Table III.
Mortality in hospitalized COVID19 patients with deep vein thrombosis
| Mortality (9 patients) | No mortality (23 patients) | ||
|---|---|---|---|
| Sex (M/F) | 8/1 | 16/7 | |
| Age, y (mean; range) | 71.2 (62–83) | 58.8 (30–94) | P < .05 |
| Comorbidities (mean) | 4 (3–5) | 3 (2–4) | |
| Oxygen therapy | |||
| High flow | - | 4 | |
| Noninvasive mechanical ventilation | 4 | 7 | |
| Invasive mechanical ventilation | 5 | 12 | |
| Localization thrombosis | |||
| Lower limb proximal | 5 | 7 | |
| Lower limb distal | 2 | 10 | |
| Upper limb | 2 | 6 | |
| Evidence pulmonary embolism | 4 | 4 | |
| Padua score (mean; range) | 3.6 (3–4) | 3.2 (3–4) | |
| Platelet (mean: range) | |||
| At admission | 222 (154–289) | 255 (63–526) | |
| At diagnosis | 272 (112–669) | 242 (139–324) | |
| Fibrinogen | |||
| At admission | 599 (367–700) | 450 (219–775) | P < .05 |
| At diagnosis | 418 (122–657) | 397 (172–717) | |
| PT | |||
| At admission | 72.2 (51–83) | 74.8 (49–93) | |
| At diagnosis | 57.6 (37–74) | 75.7 (36–118) | P < .05 |
| aPTT | 25 (20–34) | 25 (20–43) | |
| D-dimers | |||
| At admission | 13,875 (1712–35,000) | 6,682 (488–35,000) | P < .001 |
| At diagnosis | 25,270 (10,800–35,000) | 14,430 (985–35,000) | P < .001 |
| LDH | 482 (276–778) | 437 (250–876) | |
| Creatine kinase | 362 (15–2264) (100) | 124 (15–842) (78) | |
| CRP | |||
| At admission | 15.9 (7.3–27.0) | 20.2 (5.4–37.4) | |
| At diagnosis | 26.3 (1.4–100) | 16.7 (0.1–33.6) | P < .05 |
| WBC | |||
| At admission | 8.9 (6.0–14.7) | 10.9 (2.1–29.0) | |
| At diagnosis | 10.4 (1.4–21.3) | 10.6 (3.7–18) | |
Laboratory values refer to the time of diagnosis unless otherwise specified.
CRP, C-reactive protein (mg/dL) platelet (×103/ mcL); PT, prothrombin time (%); aPTT, activate thromboplastin time (%); D-Dimers (mcg/L); LDH, lactate dehydrogenase (mU/mL); creatine kinase (mU/mL); WBC, white blood count.